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SUMMARY 
Objective Caveolin-1 (CAV-1) plays important roles in many aspects of cellular biology, including 
vesicular transport, cholesterol homeostasis and signal transduction. The aim of the present study 
was to explore gene expression levels of CAV-1 in human adipose tissue in obesity and obesity-
associated type 2 diabetes mellitus (T2DM) and to analyse its potential implication in the 
inflammatory state associated with obesity. 
Design and methods Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) 
obtained from 15 females were used in the study. Patients were classified as lean (BMI 20·8 ± 1·0 
kg/m2) or obese (BMI 50·5 ± 2·6 kg/m2). The obese group was further subclassified as 
normoglycaemic (NG) or patients with T2DM. Anthropometric measurements as well as circulating 
metabolites, hormones and adipokines were determined. Real-time polymerase chain reaction (PCR) 
analyses were performed to quantify transcript levels of CAV-1 and monocyte chemoattractant 
protein (MCP-1).  
Results The presence of CAV-1 protein was detected in VAT and SAT by immunohistochemistry. 
Both obese NG and with T2DM patients exhibited significantly higher CAV-1 expression levels in 
VAT and SAT compared with lean subjects (P < 0·05). No differences between obese NG and 
T2DM patients were observed in VAT. However, obese T2DM patients were found to have higher 
CAV-1 expression levels in SAT (P < 0·05) compared with obese NG patients. A significant 
correlation was found between CAV-1 mRNA expression levels in VAT and different circulating 
inflammatory markers such as sialic acid (SA) (P < 0·001) and fibrinogen (P < 0·001) as well as 
with MCP1 mRNA expression (P < 0·05).  
Conclusion Our findings show for the first time the upregulation of mRNA CAV-1 expression levels 
in VAT and SAT of obese NG and obese T2DM patients compared with lean controls, suggesting a 
role for CAV-1 in obesity and T2DM development. The association with different inflammatory 
markers further suggests an implication of CAV-1 in the low-grade inflammation accompanying 
obesity. 
 
Correspondence: Dr Gema Frühbeck, Department of Endocrinology, Clínica Universitaria de 
Navarra, University of Navarra, Avda. Pío XII 36, 31008 Pamplona, Spain. Tel: +34 948255400 (ext. 
4484); Fax: +34 948296500; E-mail: gfruhbeck@unav.es
INTRODUCTION 
Caveolae are 50–100 nm flask-shaped invaginations of the plasma membrane implicated in a 
wide range of cellular functions such as endocytosis, apoptosis, cholesterol homeostasis, 
proliferation and signal transduction.1–4 Caveolae are present in most cell types but they are 
particularly abundant in adipocytes,5 where they have been postulated to serve as a major site 
for the initiation of insulin signalling.6 Caveolin-1 (CAV-1), a 22 kDa integral membrane 
protein, was determined to be an essential protein constituent of membrane caveolae. 7
Previous studies in knockout mice show that despite being hyperphagic, adult Cav-1 null mice are 
lean, resistant to diet-induced obesity and exhibit reduced fat pads compared with wild type 
littermates.8 Furthermore, a role for CAV-1 in insulin signalling and, consequently, its potential 
involvement in diabetes have been put forward.9,10 It has been reported that young Cav-1 knockout 
mice fed a normal diet have a blunted response to an insulin tolerance test. In addition, Cav-1 
knockout mice fed a high-fat diet developed significant postprandial hyperinsulinaemia.10 On 
further analysis, it has been reported that CAV-1 can interact with the â-subunit of the insulin 
receptor and enhance insulin-mediated phosphorylation of insulin receptor substrate (IRS)-1·11,12 
However, this finding is controversial because other studies conclude that insulin receptor 
expression and signalling is independent of CAV-1 expression.13,14
Obesity and insulin resistance are associated with a chronic inflammatory response, 
characterized by abnormal cytokine production, increased synthesis of acute-phase reactants and 
the activation of proinflammatory signalling pathways.15–17 The participation of CAV-1 in the 
inflammatory cascade is based on its role in signal transduction via interaction with diverse 
elements of the inflammatory response such as endothelial nitric oxide synthase, Ras, Src and 
protein kinase C.18,19
As body fat (BF) represents a key peripheral organ in energy balance and given the link between 
obesity, insulin resistance and inflammation,20 in the present study we examined CAV-1 expression 
in human adipose tissue and its association with different markers of inflammation in a well-
characterized group of subjects including lean, obese normoglycaemic (NG) and obese (OB) type 2 
diabetes mellitus (T2DM) women. 
 
MATERIALS AND METHODS  
Experimental subjects 
Paired samples of adipose tissue obtained from the omental and subcutaneous depots of 5 lean 
(LN) and 10 obese (OB) female individuals were used in the study. Subjects were recruited from 
healthy volunteers and patients attending the Endocrinology and Surgery Departments of the 
University Clinic of Navarra. Patients underwent a clinical assessment including medical history, 
physical examination, body composition analysis, comorbidity evaluation as well as nutritional 
interviews performed by a multidisciplinary consultation team. Patients with signs of infection 
were excluded. All females included in the study were in a premenopausal state. Patients were 
classified as obese according to both body mass index (BMI >_ 30 kg/m2; LN: 20·8 ± 1·0 kg/m2, 
OB: 50·5 ± 2·6 kg/m ) and body fat percentage (BF >_ 35%; LN: 28·1 ± 3·0%, OB: 55·2 ± 1·1%). 
BMI was calculated as weight in kilograms divided by the square of height in meters and body fat 
was estimated by air-displacement plethysmography (Bod-Pod®, Life Measurements, Concord, 
CA).21 To determine the effects of T2DM on gene expression, obese volunteers were subclassified 
into two groups according to the presence or absence of T2DM. All lean and obese NG patients 
exhibited plasma glucose concentrations < 5·6 mmol/l after fasting and < 7·8 mmol/l 2 h after an 
oral glucose tolerance test (OGTT). Definition for T2DM was based on fasting plasma glucose 
concentrations >_ 7·0 mmol/l or glycaemia >_ 11·2 mmol/l 2 h after an OGTT. T2DM subjects 
were not on oral antidiabetics or other medication likely to influence endogenous insulin levels 
since they were first diagnosed when entering the study. The samples were collected from patients 
undergoing either bariatric surgery (for OB patients) or Nissen fundoplication (for LN volunteers). 
Both interventions were carried out via a laparoscopic approach. Tissue samples were 
immediately frozen in liquid nitrogen and stored at –80 °C for gene expression analysis. The study 
was approved by the hospital’s Ethical Committee responsible for research and informed consent 
of participants was obtained. 
 
Blood assays 
Plasma samples were obtained by venipuncture after an overnight fast. Glucose was analysed by an 
automated analyser (Hitachi Modular P800, Roche, Basel, Switzerland), with quantification being 
based on enzymatic spectrophotometric reactions. Insulin was measured by means of an enzyme-
amplified chemiluminescence assay (IMMULITE®, Diagnostic Products Corp, Los Angeles, CA). 
Insulin sensitivity was calculated using the homeostasis model assessment (HOMA) [fasting 
glucose (mmol/l) x fasting insulin (µU/ml)/22·5] and QUICKI [1/(log fasting insulin (µU/ml) + log 
fasting glucose (mg/dl)] indices. Total cholesterol concentration was determined by an enzymatic 
spectrophotometric method (Boehringer Mannheim, Mannheim, Germany). High-density 
lipoprotein (HDL) cholesterol was quantified by a colorimetric method in a Beckman Synchron® 
CX analyser (Beckman Instruments Ltd, Bucks, UK). Low-density lipoprotein (LDL) cholesterol 
was calculated by the Friedewald formula as previously described.17
Fibrinogen concentrations were determined according to the method of Clauss using a 
commercially available kit (Hemoliance®, Instrumentation Laboratory, Barcelona, Spain) as 
previously described.17 High sensitivity C-reactive protein (CRP) concentrations were quantified 
using the Tina-quant® CRP (Latex) ultrasensitive assay (Roche). Leptin was measured by a 
double-antibody radioimmunoassay (RIA) method (Linco Research Inc, St. Charles, MO). Intra- 
and interassay coefficients of variation (CVs) were 5·0% and 4·5%, respectively. Adiponectin was 
determined using a commercially available ELISA kit (Biovendor, Heilderberg, Germany). Intra- 
and interassay CVs were 6·7% and 7·8%, respectively. Monocyte chemoattractant protein (MCP-
1) and tumour necrosis factor-a (TNF-a) protein levels were assessed using commercially 
available ELISA kits (R & D Systems Europe Ltd, Abingdon, UK) according to the 
manufacturer’s instructions. The intra- and interassay CVs were 7·8% and 6·7% for MCP-1, and 
5·2% and 7·4% for TNF-a, respectively. Serum amyloid A (SAA) concentrations were determined 
by ELISA (BioSource International Inc, Camarillo, CA), with intra- and interassay CVs being 
4·9% and 7·9%, respectively. Total sialic acid (SA) was assayed using a spectrophotometric 
enzymatic method (Roche). 
 
RNA extraction and real-time PCR 
Adipose tissue RNA isolation was performed by homogenization with an ULTRA-TURRAX® T 
25 basic (IKA® Werke GmbH, Staufen, Germany) using TRIzol® Reagent (Invitrogen, Barcelona, 
Spain). Samples were purified using the RNeasy Mini kit (Qiagen, Barcelona, Spain) and treated 
with DNase (RNase-free DNase Set, Qiagen). For first strand cDNA synthesis constant amounts of 
1 µg of total RNA were reverse transcribed in a 20 µl final volume using random hexamers 
(Roche) as primers and 200 units of M-MLV reverse transcriptase (Invitrogen) as previously 
described.22,23
The transcript levels for CAV-1, and MCP-1 were quantified by real-time reverse transcription (RT)-
PCR (7300 Real Time PCR System, Applied Biosystem, Foster City, CA). Primers and probes were 
designed using the software Primer Express 1·0 (Applied Biosystems) and purchased from Proligo 
(Sigma-Aldrich, Lyon, France). The following primers and TaqMan probe were used for CAV-1 
(NM_001753) amplification: forward 5′AACGATGACGTGGTCAAGATTG3′, reverse 
5′TCCAAATGCCGTCAAAACTGT3′ and probe 5′FAM-
TTGAAGATGTGATTGCAGAACCAGAAGGGATAMRA3′. The primers used for MCP-1 
(NM_002982) amplification were as follows: forward 5′GCTCATAGCAGCCACCTTCATT3′, 
reverse 5′TCTGCACTGAGATCTTCCTATTGGT3′ and probe 5′FAM-
TCGCTCAGCCAGATGCAATCAATGC-TAMRA3′. TaqMan probes encompassing fragments 
from extremes of two exons were designed to ensure the detection of the corresponding transcript 
avoiding genomic DNA amplification. The cDNA was amplified at the following conditions: 95 
°C for 10 min, followed by 45 cycles of 15 s at 95 °C and 1 min at 59 °C, using the TaqMan® 
Universal PCR Master Mix (Applied Biosystems). The primer and probe concentrations for gene 
amplification were 300 nmol/l and 200 nmol/l, respectively. All results were normalized to the 
levels of the ribosomal 18S Rrna24 (Applied Biosystems) and relative quantification was 
calculated using the AACt formula. Relative mRNA expression was expressed as fold 
expression over the calibrator sample (average of gene expression corresponding to the lean 
group). All samples were run in triplicate and the average values were calculated. 
 
Immunohistochemistry 
The immunohistochemistry was carried out using the indirect immunoperoxidase method. Sections (4 
µm) of formalin-fixed paraffin-embedded visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SAT) were dewaxed in xylene, rehydrated in decreasing concentrations of ethanol and 
treated with 3% H2O2 (Sigma, Steinhein, Germany) in absolute methanol for 10 min at room 
temperature (RT) to quench endogenous peroxidase activity. Then, sections were immersed in 10 
mmol/l citrate buffer (pH 6·0) and heated using a microwave oven at 800 W for 15 min to enhance 
antigen retrieval. After cooling, slides were blocked during 1 h with 1% murine serum (Sigma) 
diluted in Tris-buffer saline (TBS) (50 mmol/l Tris, 0·5 mol/l NaCl; pH 7·36) to prevent 
nonspecific adsorption. Sections were incubated overnight at 4 °C with rabbit anticaveolin-1 
(Sigma) antibody diluted 1 : 100 in TBS. After three washes (5 min each) with TBS, sections were 
incubated with horseradish peroxidase conjugated antirabbit (Amersham Biosciences, Little 
Chalfont, Buckinghamshire, UK) polyclonal IgG diluted 1 : 100 in TBS for 30 min at RT. After 
washing in TBS, peroxidase reaction was visualized with a 3·3′diaminobenzidine (DAB, 
Amersham Biosciences) and/or H2O2 solution (0·5 mg/ml DAB, 0·03% H2O2 diluted in 50 
mmol/l Tris-HCl, pH 7·36), as chromogen and Harris haematoxylin solution (Sigma) as counter-
staining. Sections were dehydrated, cover-slipped and observed under a Zeiss Axiovert 40 CFL 
optic microscope (Zeiss, Göttingen, Germany). Negative control slides without primary antibody 
were included to assess nonspecific staining. 
 
Data analysis 
Data are presented as mean ± standard error of the mean (SEM). SAA values did not follow a 
normal distribution and were logarithmically transformed for statistical analysis. These values are 
presented as median (interquartile range). Differences between groups were assessed by one-way 
analysis of the variance (ANOVA) followed by least significant difference (LSD) tests. Pearson’s 
correlation coefficients (r) were used to analyse the association between variables. The 
calculations were performed using the SPSS for Windows version 13·0 statistical package (SPSS, 
Chicago, IL). A P-value < 0·05 was considered statistically significant. 
 
RESULTS AND DISCUSSION 
A summary of biochemical and hormonal characteristics of the subjects is shown in Table 1. The 
obese patients included in our study showed significantly higher BF (P < 0·01) and leptin 
concentrations (P < 0·05), together with lower HDL-cholesterol levels (P < 0·01) when compared 
with the lean volunteers. Obese T2DM patients had significantly increased glucose concentrations in 
the fasting state (P < 0·01) and 2 h after an OGTT (P < 0·01) in comparison with NG obese 
volunteers, and exhibited lower concentrations of adiponectin (P < 0·05) in comparison with lean 
subjects. As expected obese NG and T2DM also showed significantly increased concentrations of 
inflammatory biomarkers than lean subjects: CRP (P < 0·01), fibrinogen (P < 0·05), MCP-1 (P < 
0·01), SAA (P < 0·05) and TNF-a (P < 0·05). SA levels were only significantly increased in obese 
T2DM patients compared with lean volunteers (P < 0·05). 
Because depot-specific differences have been established as regards comorbidity development, the 
analyses were carried out in adipose tissue samples obtained from both the visceral and 
subcutaneous locations.25 The presence of CAV-1 protein in sections of VAT (Fig. 1a) and SAT 
(Fig. 1b) was evaluated by immunohistological analysis in obese NG and T2DM subjects. Both 
adipocytes and cells of the stromovascular fraction (SVF) of VAT and SAT were immunopositive 
for CAV-1. CAV-1 expression levels in both VAT (P < 0·05) and SAT (P < 0·001) were positively 
correlated to BMI and BF (Table 2). Real-time PCR analysis indicated that CAV-1 expression levels 
in VAT were significantly higher in obese NG subjects (P = 0·008) and obese T2DM patients (P = 
0·043) than in lean controls, while no differences between obese NG and T2DM patients were 
observed (Fig. 2). CAV-1 expression levels in SAT followed a similar trend, being significantly 
increased in obese NG subjects (P = 0·002) and obese T2DM patients (P < 0·0001) compared with 
the lean group. However, CAV-1 expression levels in the subcutaneous depot were higher in obese 
T2DM patients compared with obese NG subjects (P = 0·027) (Fig. 2). 
These results are in accordance with previous results in Cav-1 knockout mice, which developed 
progressive adipose tissue atrophy and resistance to diet-induced obesity due to an inability to gain 
fat mass.8 It has been reported that white adipose tissue from Cav-1–/– mice displays heterogeneity 
in lipid droplets with a tendency towards smaller adipocytes. The smaller lipid droplets indicate 
that Cav-1 null adipocytes are incapable of lipogenesis during times of lipid excess.8 The 
significantly higher SAT and VAT expression levels of CAV-1 in our obese patients compared with 
the lean volunteers may indicate an enhanced lipid storing ability of adipocytes in human obesity. 
Furthermore, CAV-1 is involved not only in lipogenesis but also in the adipogenic process as CAV-
1 mRNA and protein levels increase over 25-fold during the differentiation of mouse 3T3-L1 
fibroblasts into adipocytes,5 which is in agreement with our observed increased expression in 
obesity. 
Insulin plays an important role in the regulation of adipose tissue homeostasis because it stimulates 
de novo lipogenesis as well as inhibits lipolysis.26,27 Analysis in Cav-1 knockout mice revealed a 
90% decrease of detectable insulin receptor levels in adipose tissue.10 A role for CAV-1 in insulin 
signalling has been established.28–30 Interestingly, two mutations of the human insulin receptor 
located within the established CAV-1 binding motif (W1193L and W1200S) reportedly result in 
severe insulin resistance.31,32 In the present study T2DM patients showed higher CAV-1 expression 
levels in SAT, which may reflect an attempt to improve signalling in the setting of increased insulin 
resistance. 
CAV-1 expression levels were positively correlated to MCP-1 mRNA in VAT (r = 0·66, P = 0·011) 
and in SAT (r = 0·68, P = 0·031). MCP-1 expression levels were significantly upregulated (P < 0·05) 
in VAT for both obese NG (4·5-fold) and T2DM (4·2-fold) patients compared with lean volunteers. 
A similar trend was found in SAT although no significant differences were observed. CAV-1 
expression levels were positively correlated in both depots to other inflammatory markers such as 
plasma CRP and SA (Table 2). Moreover, a positive association of circulating concentrations of 
fibrinogen and SAA with CAV-1 mRNA in VAT was observed (Table 2). However, when the 
analysis was adjusted for age and BMI, only SA (r = 0·76, P = 0·007) and fibrinogen (r = 0·61, P = 
0·033) still retained a significant positive correlation with CAV-1 mRNA levels in VAT, while the 
significance with inflammatory markers was lost in SAT (Table 2). The production and release of 
inflammatory cytokines has been previously reported to be increased in VAT,33,34 suggesting that 
this depot is more proinflammatory. The significant correlation between circulating SAA 
concentrations and CAV-1 mRNA in SAT may be related to the role of this acute-phase protein in 
HDL-cholesterol metabolism by promoting cellular cholesterol efflux through a number of different 
pathways.35 Interestingly, CAV-1 also actively plays an important role in the regulation of 
intracellular cholesterol homeostasis.36 The different correlation pattern between CAV-1 mRNA 
expression and proinflammatory factors observed in VAT and SAT provides further evidence for 
the diverse depot-specific contributions to comorbidity development.25 The more prominent 
involvement of SAT in lipid metabolism as opposed to VAT, which is more related to inflammation 
and insulin resistance, may underlie the depot-specific differences regarding the diverse correlation 
pattern observed in both adipose tissue locations. In our study, the association of mRNA CAV-1 
levels in VAT with different inflammatory markers suggests an implication of CAV-1 in the low-
grade inflammation characteristic of visceral obesity. Elucidating the nature of this implication and 
the teleological significance requires further research. An involvement of CAV-1 in inflammation 
has been previously suggested.18 CAV-1 mRNA expression has been shown to be induced by 
cytokines such as TNF-á and IL-1â37 with numerous cytokine receptors being localized in 
caveolae.38 Similar to suppressor of cytokine signalling (SOCS) proteins, CAV-1 might regulate 
cytokine signalling through direct interactions with members of the JAK family, associations 
with cytokine receptors and the proteasoma pathway.4,39
In conclusion, we show for the first time in humans that obesity and obesity-associated T2DM are 
characterized by an increased CAV-1 mRNA expression in VAT and SAT. Moreover, this 
expression is correlated with different inflammatory markers in VAT. Our data suggests an 
involvement of CAV-1 in obesity development as well as in adipose-related insulin signalling in 
humans. Unravelling the clinical relevance of the role of CAV-1 in these conditions remains to be 
fully elucidated. 
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Table 1. Anthropometric and biochemical characteristics of women included in the study 
 Lean Obese NG Obese T2DM 
N 5 5 5 
Age (years) 38 ± 4 36 ± 5 43 ± 3 
BMI (kg/m2) 20·8 ± 1·0 48·4 ± 2·0* 52·6 ± 4·9* 
Body fat (%) 28·1 ± 3·0 56·3 ± 1·1† 55·0 ± 1·8† 
Fasting glucose (mmol/l) 5·1 ± 0·2 4·9 ± 0·3 7·6 ± 0·6†,$ 
2 h OGTT glucose (mmol/l) 6·0 ± 0·6 6·4 ± 0·3 14·7 ± 2·4†,$ 
Fasting insulin (mmol/l) 57·7 ± 12·5 140·4 ± 36·7 176·3 ± 49·9* 
2 h OGTT insulin (mmol/l) 81·9 ± 13·3 804·2 ± 333·8* 707·5 ± 145·1* 
HOMA 1·7 ± 0·4 4·0 ± 1·1 8·1 ± 2·9* 
QUICKI 0·363 ± 0·017 0·320 ± 0·013 0·297 ± 0·015† 
Cholesterol (mmol/l) 4·8 ± 0·3 4·8 ± 0·4 5·2 ± 0·3 
LDL-cholesterol (mmol/l) 3·4 ± 0·2 3·2 ± 0·3 3·5 ± 0·2 
HDL-cholesterol (mmol/l) 1·4 ± 0·1 1·0 ± 0·0† 1·0 ± 0·0† 
Leptin (ng/ml) 9·1 ± 1·7 57·6 ± 7·6* 69·3 ± 19·6† 
Adiponectin (µg/ml) 11·2 ± 2·4 8·8 ± 0·8 4·8 ± 0·5* 
C-reactive protein (mg/l) 2·00 ± 0·45 6·40 ± 0·81† 8·80 ± 1·36† 
Fibrinogen (g/l) 2·60 ± 0·34 4·04 ± 0·23† 3·41 ± 0·14* 
MCP-1 (µl/l) 107·8 ± 11·5 162·6 ± 18·3* 178·8 ± 15·0† 
SAA (mg/l)§ 4·7 (3·3–13·2) 28·2 (7·9–30·2)* 16·5 (8·4–61·7)* 
SA (mmol/l) 29·7 ± 5·1 39·4 ± 3·7 46·7 ± 5·0* 
TNF-a (µg/l) 1·0 ± 0·1 1·9 ± 0·4* 1·9 ± 0·2* 
Data are mean ± SEM for normally distributed variables and median (interquartile range) for the 
skewed variable SAA. Differences between both groups were analysed by one-way anova followed by 
LSD tests. *P < 0·05 and †P < 0·01 vs. lean. ‡P < 0·01 vs. NG obese. §SAA values were logarithmically 
transformed for statistical analysis. 
NG, normoglycaemic; T2DM, type 2 diabetes mellitus; BMI, body mass index; 
OGTT, oral glucose tolerance test; HOMA, homeostasis model assessment; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
MCP, monocyte chemoattractant protein; SAA, serum amyloid A; SA, sialic acid. 
 Table 2. Univariate analysis of the correlation between caveolin-1 (CAV-1) mRNA and several 
inflammatory-related variables in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) 
unadjusted and after adjusting for age and body mass index (BMI) 
Unadjusted  
Age-
adjusted  
Age- and BMI-
adjusted  
r P r P r P 
VAT       
BMI 0·58 0·030 0·63 0·022 – – 
Body fat 0·66 0·010 0·78 0·002 0·71 0·010 
C-reactive protein 0·55 0·040 0·63 0·021 0·19 0·554 
SA 0·56 0·048 0·85 < 0·001 0·76 0·007 
SAA 0·63 0·022 0·59 0·041 0·11 0·744 
Fibrinogen 0·73 0·003 0·76 0·002 0·61 0·033 
SAT       
BMI 0·95 < 0·0001 0·91 0·001 – – 
Body fat 0·89 0·001 0·84 0·005 –0·10 0·812 
C-reactive protein 0·90 0·001 0·87 0·003 0·25 0·543 
SA 0·73 0·017 0·68 0·044 0·29 0·490 
SAA 0·48 0·144 0·65 0·06 –0·83 0·011 
Fibrinogen 0·47 0·170 0·53 0·139 –0·07 0·859 
BMI, body mass index; SA, sialic acid; SAA, serum amyloid A. 
 
 
 
 
 
 
 Fig. 1 Immunostaining of CAV-1 in human (a) visceral adipose tissue (VAT) and (b) subcutaneous 
adipose tissue (SAT) of normoglycaemic (NG) and type 2 diabetes mellitus (T2DM) obese 
patients. Strong positivity (brown staining) was observed for CAV-1 in both fully mature 
adipocytes and cells of the stromovascular fraction of SAT and VAT (B, C, E and F). No 
immunoreactivity was found without the primary antibody (negative control) (A and D). Images 
are representative of immunostaining in VAT and SAT from 6 obese subjects. A, B, D and E: × 
100 (scale bar = 80 μm); C and F: × 400 (scale bar = 20 μm). 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2 Real-time polymerase chain reaction (PCR) analysis of CAV-1 transcript levels in visceral 
adipose tissue (VAT) and subcutaneous adipose tissue (SAT) of lean (LN), obese normoglycaemic 
(OB NG) and obese type 2 diabetes mellitus (OB T2DM) volunteers. Bars represent the mean ± 
SEM of the ratio between CAV-1–18S rRNA. The expression of CAV-1 in lean subjects was 
assumed to be 1. Differences between groups were analysed by one-way anova followed by LSD 
tests. *P < 0·05 and **P < 0·01 vs. LN regarding CAV-1 expression levels in VAT and §§P < 0·01 
vs. LN in SAT. †P < 0·05 vs. OB NG (N = 5 per group). 
